Delaware
|
33-0655706
|
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
(I.R.S. Employer
Identification No.)
|
1100 Massachusetts Avenue, Floor 4
Cambridge, Massachusetts
|
02138
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
Non-accelerated filer
|
☒
|
Smaller reporting company
|
☒
|
Emerging growth company
|
☐
|
Item 1. |
Plan Information.
|
Item 2. |
Registrant Information and Employee Plan Annual Information.
|
Item 3. |
Incorporation of Documents by Reference.
|
Item 4. |
Description of Securities.
|
Item 5. |
Interests of Named Experts and Counsel.
|
Item 6. |
Indemnification of Directors and Officers.
|
• |
for any breach of the director’s duty of loyalty to the Registrant or its stockholders;
|
• |
for acts or omissions by the director not in good faith or which involve intentional misconduct or a knowing violation of law;
|
• |
for declaring dividends or authorizing the purchase or redemption of shares in violation of Delaware law; or
|
• |
for transactions where the director derived any improper personal benefit.
|
Item 7. |
Exemption from Registration Claimed.
|
Item 8. |
Exhibits.
|
Number
|
Description
|
|
Restated Certificate of Incorporation of the Registrant, as amended (previously filed as Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended July 30, 2020 (File No. 000-31141) and incorporated herein by
reference).
|
||
Amended and Restated Bylaws of the Registrant (previously filed as Exhibit 3.2 to the Registrant’s Annual Report on Form 10-K filed on March 28, 2023 (File No. 000-31141) and incorporated herein by reference).
|
||
Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant. Filed Herewith.
|
||
Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1). Filed Herewith.
|
||
Consent of Ernst & Young LLP, independent registered public accounting firm to the Registrant. Filed Herewith.
|
||
Power of attorney (included on the signature pages of this Registration Statement).
|
||
Form of Nonstatutory Stock Option Award Agreement for Inducement Grant Pursuant to Nasdaq Stock Market Rule 5635 (c)(4) (previously filed as Exhibit 99.1 to the Registrant’s Form S-8 Registration Statement filed on August 2, 2021 (File No.
333-258360) and incorporated herein by reference).
|
||
Filing Fee Table
|
Item 9. |
Undertakings.
|
INFINITY PHARMACEUTICALS, INC.
|
||
By:
|
/s/ Lawrence E. Bloch
|
|
Lawrence E. Bloch, M.D., J.D.
|
||
President
|
Signature
|
Title
|
Date
|
||
/s/ Adelene Q. Perkins
|
Chief Executive Officer and Chair of the Board of Directors (Principal Executive Officer)
|
March 28, 2023
|
||
Adelene Q. Perkins
|
||||
/s/ Lawrence E. Bloch
|
President (Principal Financial Officer and Principal Accounting Officer)
|
March 28, 2023
|
||
Lawrence E. Bloch, M.D., J.D.
|
||||
/s/ Samuel Agresta
|
Director
|
March 28, 2023
|
||
Samuel Agresta, M.D., M.P.H.
|
||||
/s/ David Beier
|
Director
|
March 28, 2023
|
||
David Beier, J.D.
|
||||
/s/ Anthony B. Evnin
|
Director
|
March 28, 2023
|
||
Anthony B. Evnin, Ph.D.
|
||||
/s/ Richard Gaynor
|
Director
|
March 28, 2023
|
||
Richard Gaynor, M.D.
|
||||
/s/ Sujay R. Kango
|
Director
|
March 28, 2023
|
||
Sujay R. Kango
|
||||
/s/ Brian Schwartz
|
Director
|
March 28, 2023
|
||
Brian Schwartz, M.D.
|
||||
/s/ Norman C. Selby
|
Director
|
March 28, 2023
|
||
Norman C. Selby
|
March 28, 2023
|
Exhibit 5.1
|
+ 1 617 526 6000 (t)
|
|
Infinity Pharmaceuticals, Inc.
1100 Massachusetts Avenue, Floor 4
Cambridge, Massachusetts 02138
|
+ 1 617 526 5000 (f)
|
Infinity Pharmaceuticals, Inc.
March 28, 2023 Page 2
|
|
|
![]() |
By:
|
/s/ Wilmer Cutler Pickering Hale and Dorr LLP
|
WILMER CUTLER PICKERING
|
|
HALE AND DORR LLP
|
Security
Type
|
Security Class
Title
|
Fee
Calculation
Rule
|
Amount
Registered
(1)
|
Proposed
Maximum
Offering
Price Per
Unit
|
Maximum
Aggregate
Offering Price
|
Fee Rate
|
Amount of
Registration
Fee
|
|||||||||||||
Equity
|
Common Stock, $0.001 par value per share
|
Other
|
30,000 shares (2)
|
$0.1921 (3)
|
$5,763.00 (3)
|
$110.20
per $1,000,000
|
$0.64
|
|||||||||||||
Total Offering Amounts
|
$5,763.00
|
$0.64
|
||||||||||||||||||
Total Fee Offsets
|
—
|
|||||||||||||||||||
Net Fee Due
|
$0.64
|
(1) |
In accordance with Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall be deemed to cover any additional securities that may from time to time be
offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.
|
(2) |
Consists of 30,000 shares issuable under a nonstatutory stock option award pursuant to a nonstatutory stock option agreement entered into by the Registrant with Kenneth Duong, the Registrant’s Associate
Director, Supply Operations, which was granted on April 6, 2022 in accordance with Nasdaq Listing Rule 5635(c)(4).
|
(3) |
Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act. The price per share and aggregate offering price are calculated on the basis of
the average of the high and low sale prices of the registrant’s common stock on the Nasdaq Global Market on March 24, 2023, in accordance with Rule 457(c) under the Securities Act.
|
/4"OE.@#TOP-\*;WQYH[:M-K:6L(E:%08S,_ !.1N&.OK
M7T)X2\/CPKX7LM%6Z>Z%JK#SG7:6RQ;IDX SCKT%>.?L^>(/*OM2\/ROA9E%
MU #_ 'AA7'U(VG_@)KWV@#R+QM\%9?%/B6\UNWUT0O(K#6I]?65[23>8(K8@-P1C<6]_2O2/"GARU
M\*>&[32+0 K"N9),
"_$+]C7Q#XSL_&EK!XTT6V;
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MAU+3-6TO4WT_5-(U6RL_6OA)\!/QHA\5CPK;^,='U;P-K\7AOQ=X7^('@3
MQ=\.O%FA:C=Z58:]IDEWX=\9Z1HVI2Z;K.B:G8:II&KV<-SI=_;S210W9O+.
M_M;7Y0UC]F#XU?&'7O%?Q"^,WB3X;Z!XTN_!'PZ^&GA'0_AY;^)[[PMI>@^%
M?B=8_$[QMK^KWNM3V>IZIJOCG5M'T.ST;2Y+ ./'^I^$-'\$:/INFVNCS:GX@B\6
MZCX]\)0>'M7\/VFIZ+JRZQ'/9:C-;VU[+;